Dr. Ruba presents a case study highlighting treatment approach with acalabrutinib and focus on safety profile of BTKi.
Dr. Ruba Taha, Qatar
Edit Video Component
Dr. Ruba Taha, Consultant Clinical Haematologist, Hamad Medical Corporation, Qatar, elaborates 2nd GCC Haematology forum- CLL case discussion Focus on safety profile of BTKi.
• Discusses a patient case with his background and treatment approach with acalabrutinib, summarises 3 clinical trial data.
• Serious adverse events from FLAIR trial, GLOW trial
• Updated Ibrutinib smpc for serious cardiac events. In the later section
• Clinical evidence of acalabrutinib over Ibrutinib from ELEVATE-TN trial data
• ALPINE study: Zanubrutinib in head-to-head comparison with Ibrutinib.
• NCCN guidelines treatment regime for CLL/SLL.
Explore more videos
Configure Image Component
CLL Case Presentation
Dr. Khalil Al Farsi, Oman
Configure Image Component
Expert Guidance for the Treatment of CLL
Dr. Susan M. O'Brien, US
Configure Image Component
Panel discussion
Dr. Ayman Al Hejazi, KSA
Modal Window Component Section Begins
Modal Window Component Section Ends